Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

IntelGenx enters VetaFilm development license agreements under new animal health partnership

IntelGenx (TSX:IGX; OTCQB:IGXT) entered into development and license agreements with a wholly owned subsidiary of Covenant Animal Health Partners, who will fund the development and manufacturing of a VetaFilm-based drug...

December 18, 2023

Executive Moves

Sigyn Therapeutics names Jerry DeCiccio as CFO

Sigyn Therapeutics (OTCQB:SIGY) appointed Jerry DeCiccio as CFO, succeeding Jeremy Farrell, who was appointed CFO in March of 2022. Mr. DeCiccio has more than 40 years of financial industry experience, previously...

December 12, 2023

Developments Markets

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Hepion Pharmaceuticals (NASDAQ:HEPA) announced a restructuring that, among other things, will suspend the enrollment of new patients in the Phase 2b ‘ASCEND-NASH’ clinical trial of its lead drug candidate, rencofilstat...

December 7, 2023

Developments

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Anixa Biosciences (NASDAQ:ANIX) and its partner, Cleveland Clinic, presented positive new results from the Phase 1 clinical trial of Anixa’s breast cancer vaccine at the 2023 San Antonio Breast Cancer Symposium (SABCS)...

December 7, 2023

Markets

Evercore starts Gracell Biotech at OP

Evercore ISI initiated coverage of Gracell Biotechnologies (NASDAQ:GRCL) with an “outperform” rating and no price target. The stock was quoted at $5.43 midday on Nov. 27. Gracell is developing a unique CAR-T construct...

November 27, 2023

Developments

Anixa reports European patent for ovarian cancer vaccine technology

Anixa Biosciences (NASDAQ:ANIX) reported that its partner, Cleveland Clinic, received an intention-to-grant notice from the European Patent Office (EPO) for the patent application covering the company’s ovarian cancer...

November 27, 2023

Developments

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

SHINE Technologies and Nucleus RadioPharma entered a multi-year supply agreement for lutetium-177, a radiopharmaceutical that is used for targeted cancer treatment. Nucleus, a contract development and manufacturing...

November 17, 2023

Developments

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

PharmaJet launched a Phase 1 clinical study evaluating a Venezuelan Equine Encephalitis (VEE) DNA vaccine delivered via the company’s needle-free Precision Delivery Systems. The Phase 1 trial, sponsored by PharmaJet and...

November 17, 2023

Developments

LENZ Therapeutics, Graphite Bio in merger accord

Closely-held LENZ Therapeutics and Graphite Bio (NASDAQ:GRPH) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company, which will focus on advancing LENZ’...

November 15, 2023

Developments

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

IntelGenx (TSX:IGX; OTCQB:IGXT) reported that the Swedish Medical Products Agency, the Swedish Ethical Review Authority, and the Regional Biobank Centre approved the company’s planned clinical study to investigate the...

November 14, 2023

Developments

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Hepion Pharmaceuticals (NASDAQ:HEPA) presented new data from its Phase 2 ALTITUDE-NASH trial demonstrating that 17 weeks of rencofilstat treatment significantly reduced liver stiffness in subjects with advanced F3...

November 13, 2023

Markets

Brookline starts Annovis Bio at buy; PT $35

Brookline Capital Markets initiated coverage of Annovis Bio (NASDAQ:ANVS) with a “buy” rating and price target of $35. The stock was quoted at $5.85 midday on Nov. 10. Annovis is developing treatments for...

November 10, 2023

IntelGenx enters VetaFilm development license agreements under new animal health partnership

Sigyn Therapeutics names Jerry DeCiccio as CFO

Hepion reports restructuring and resignations; Brookline downgrades to hold and suspends target

Anixa reports positive new data from Phase 1 breast cancer vaccine trial

Evercore starts Gracell Biotech at OP

Anixa reports European patent for ovarian cancer vaccine technology

SHINE Technologies, Nucleus RadioPharma in long-term supply pact

PharmaJet launches Phase 1 trial of Precision Delivery Systems-delivered VEE vaccine

LENZ Therapeutics, Graphite Bio in merger accord

IntelGenx gets approval for Phase 2 Montelukast VersaFilm trial in Parkinson’s disease

Hepion’s rencofilstat demonstrates significant reduction in liver stiffness in patients with advanced MASH liver disease

Brookline starts Annovis Bio at buy; PT $35

General

More